Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Paediatr Child Health ; 49(2): 120-4, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23336756

ABSTRACT

AIM: Acute gastroenteritis (AGE) has been a significant component of the clinical load in the short stay unit (SSU) at the Royal Children's Hospital (RCH) since its establishment in 2004. Since the introduction of routine rotavirus immunisation in Australia in 2007 there has been a clinical impression of a substantial reduction in AGE managed in the SSU. This study aimed to examine changes in the epidemiology of AGE in the SSU, and RCH overall, between 2005 and 2009 and explore whether this reflects a change specifically in AGE due to rotavirus. METHODS: Discharge coding data for AGE from all inpatient wards, the SSU and emergency department (ED) at the RCH were examined. Stool virology results for the same period were analysed. RESULTS: Since 2007 there has been a 58% reduction in AGE admissions to the SSU. The median age of patients admitted to the RCH with rotaviral enteritis has increased from 1.3 years to 3.8 years. Presentations to the ED for AGE have fallen from 53 to 34 cases per 1000 attendances between 2004 and 2009, and admission rates from the ED have fallen from 23 to 13% of AGE presentations. Detection rates of rotavirus fell from 13.1 to 6.7% between 2005 and 2009. CONCLUSION: A marked decrease in AGE-related clinical activity and reduction in rotavirus detection at the RCH has occurred since the introduction of routine rotavirus immunisation in Australia. This has significant resource planning implications for units based on short stay models of care.


Subject(s)
Gastroenteritis/epidemiology , Hospitalization/trends , Rotavirus Infections/prevention & control , Rotavirus Vaccines , Adenoviridae/isolation & purification , Australia/epidemiology , Child , Child, Preschool , Emergency Service, Hospital/statistics & numerical data , Hospitalization/statistics & numerical data , Hospitals, Pediatric , Humans , Immunization , Infant , Infant, Newborn , Retroviridae/isolation & purification , Victoria/epidemiology
2.
Med J Aust ; 194(1): 41-3, 2011 Jan 03.
Article in English | MEDLINE | ID: mdl-21449868

ABSTRACT

Human infection with Rickettsia felis has been reported in most parts of the world, and R. felis has recently been confirmed in cat fleas in Western Australia. The clinical presentations of R. typhi and R. felis are similar, and in the past, the incidence of R. felis infection may have been underestimated. We describe the first reported cases of probable human R. felis infection in Australia. Two adults and three children in Victoria contracted a rickettsial disease after exposure to fleas from kittens. Molecular testing of fleas demonstrated the presence of R. felis but not R. typhi.


Subject(s)
Rickettsia Infections/epidemiology , Rickettsia felis , Adult , Animals , Cats/microbiology , Cats/parasitology , Child , Ctenocephalides/microbiology , Female , Humans , Male , Rickettsia Infections/diagnosis , Rickettsia Infections/etiology , Rickettsia Infections/microbiology , Siphonaptera/microbiology , Victoria/epidemiology
3.
Pediatr Infect Dis J ; 30(1 Suppl): S25-9, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21183837

ABSTRACT

INTRODUCTION: : Rotavirus vaccines were introduced into the funded Australian National Immunization Program (NIP) in July 2007. Due to purchasing arrangements, individual states and territories chose either a 2-dose RV1 (Rotarix, GSK) regimen or 3-dose RV5 (Rotateq, Merck/CSL) regimen. This allowed comparison of both vaccines in similar populations with high infant vaccination coverage. METHODS: : Admission and rotavirus identification data from the major pediatric hospitals in 3 states (2 using RV5, 1 RV1), together with state-based hospitalization and vaccination data from Queensland (RV5) were analyzed for the years before, and up to 30 months following rotavirus vaccine introduction. Emergency encounters and short-stay unit admissions for gastroenteritis are also described. RESULTS: : Rotavirus vaccine coverage in Australia is high, with 87% of infants receiving at least 1 dose. Hospital admissions for both rotavirus gastroenteritis and nonrotavirus-coded gastroenteritis were reduced following vaccine introduction in all states, not only for the age group eligible for NIP rotavirus vaccination, but also for children born prior. RV5 vaccine efficacy in Queensland has been estimated at 89.3%. Marked reductions in acute gastroenteritis emergency presentations and short-stay unit admissions have also been observed. CONCLUSIONS: : Early evidence from the NIP in Australia has demonstrated high rotavirus coverage with both RV1 and RV5. The introduction of both vaccines has been associated with a marked reduction in gastroenteritis admissions, supportive of both direct vaccine protection, as well as with indirect herd protection.


Subject(s)
Gastroenteritis/epidemiology , Gastroenteritis/prevention & control , Hospitalization/trends , Rotavirus Infections/epidemiology , Rotavirus Infections/prevention & control , Rotavirus Vaccines/immunology , Vaccination/statistics & numerical data , Child , Child, Preschool , Emergency Medical Services/statistics & numerical data , Emergency Medical Services/trends , Health Policy , Hospitalization/statistics & numerical data , Humans , Immunity, Herd , Immunization Programs , Infant , Infant, Newborn , Queensland/epidemiology , Rotavirus Vaccines/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...